Literature DB >> 25545976

Subcutaneous immunoglobulin replacement therapy: ensuring success.

M Elizabeth M Younger1, William Blouin, Carla Duff, Kristin Buehler Epland, Elyse Murphy, Debra Sedlak.   

Abstract

Subcutaneous immunoglobulin (SCIg) infusions are an option for patients requiring immunoglobulin therapy. Nurses are uniquely positioned to advocate for patients and to teach them how to successfully manage their infusions. The purpose of this review is to describe SCIg therapy and to provide teaching instructions as well as creative tips to ensure treatment success.

Entities:  

Mesh:

Year:  2015        PMID: 25545976     DOI: 10.1097/NAN.0000000000000087

Source DB:  PubMed          Journal:  J Infus Nurs        ISSN: 1533-1458


  4 in total

Review 1.  Intravenous immunoglobulin therapy: a snapshot for the internist.

Authors:  Gianfranco Vitiello; Giacomo Emmi; Elena Silvestri; Gerardo Di Scala; Boaz Palterer; Paola Parronchi
Journal:  Intern Emerg Med       Date:  2019-07-15       Impact factor: 5.472

2.  II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.

Authors:  Ekaterini Simões Goudouris; Almerinda Maria do Rego Silva; Aluce Loureiro Ouricuri; Anete Sevciovic Grumach; Antonio Condino-Neto; Beatriz Tavares Costa-Carvalho; Carolina Cardoso Prando; Cristina Maria Kokron; Dewton de Moraes Vasconcelos; Fabíola Scancetti Tavares; Gesmar Rodrigues Silva Segundo; Irma Cecília Barreto; Mayra de Barros Dorna; Myrthes Anna Barros; Wilma Carvalho Neves Forte
Journal:  Einstein (Sao Paulo)       Date:  2017

3.  Low-dose subcutaneous immunoglobulin is an effective treatment for autoimmune bullous skin disorders: A case report.

Authors:  Erin Streu; Marni C Wiseman; James B Johnston
Journal:  SAGE Open Med Case Rep       Date:  2020-01-21

4.  Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.

Authors:  Clémence Perraudin; Aline Bourdin; Alex Vicino; Thierry Kuntzer; Olivier Bugnon; Jérôme Berger
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.